Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Executive Summary
Switching, manufacturing, and indication extrapolation among worries raised in closed-door session where AbbVie argued Humira's mechanism of action is not entirely understood.
You may also be interested in...
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Industry calls for more education amid concerns that brand sales reps are encouraging providers to use only interchangeable products because they are better than biosimilars.
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Industry calls for more education amid concerns that brand sales reps are encouraging providers to use only interchangeable products because they are better than biosimilars.
Humira Biosimilar Interchangeability: The Race Begins
Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.